Beyond Celiac Investments (BCI) is an investment program designed to accelerate the development of treatments and a cure for celiac disease by leveraging the speed and scale of venture capital and capital markets. BCI launched in February of 2024 with an initial funding of $2 million.
There are no venture funds with a specific focus on celiac disease or autoimmune disorders. BCI allows us to invest significant resources to identify promising treatments under development as well as those that have been investigated or approved for other purposes that also might benefit celiac disease patients.
BCI is using the Development Catalyst business model, enabling drug development through nonprofit means. Using donated funds also means that all financial returns from BCI’s investments return to Beyond Celiac to be used for future investments and grants to benefit the celiac disease population and the Beyond Celiac mission to accelerate research for a cure.
If you’d like to learn more, support BCI directly, or get involved, please send an email to [email protected].
Opt-in to stay up-to-date on the latest news.
Yes, I want to advance research No, I'd prefer not to